Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272594 | 0.80 | CYP2D6 (0.49) | CYP2D6CYP3A4TSHRGAAALDH1A1 | |
| SCHEMBL12372531 | 0.79 | CYP2D6 (0.51) | CYP2D6CYP3A4TSHRGAAALDH1A1 | |
| SCHEMBL7248696 | 0.78 | CYP2D6 (0.46) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL12596337 | 0.77 | CYP3A4 (0.51) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL2281012 | 0.77 | CYP2D6 (0.50) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL21193226 | 0.76 | CYP2D6 (0.47) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL12465471 | 0.76 | CYP3A4 (0.50) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL3277953 | 0.76 | CYP3A4 (0.50) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL16684766 | 0.76 | OPRL1 (0.51) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL4506269 | 0.76 | CYP3A4 (0.50) | CYP2D6CYP3A4TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | CYP2D6 2287/4885CYP3A4 2784/4885TSHR 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.